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Animal studies have demonstrated that the mouse and rabbit are far more responsive to the inductive properties of rifamycin derivatives than the rat
and guinea pig. The rat hepatic cytochrome P450 system seems to be resistant to the action of rifampicin unless very high doses are used. Mouse
hepatic microsomal mixed-function oxidase activity is markedly increased by repeated dosing with rifampicin, whereas administration of rifabutin
may be ineffective. In humans, both rifampicin and rifabutin are extensively metabolized and induce their own metabolism. The induced metabolic
pathways remain essentially unknown. Under autoinduction conditions, the elimination half-life of rifampicin decreases, whereas that of rifabutin is
not altered. Although the effects of repeated administration of rifampicin and rifabutin on the various forms of cytochrome P450 in humans have not
been extensively examined, there is convincing evidence that the P4503A subfamily is induced by either drug, whereas the P4501A subfamily and
P4502D6 do not appear to be affected by rifampicin. Limited reliable information is available concerning the induction of human glucuronyltrans-
ferase activities by rifampicin and rifabutin which, however, do not seem to influence zidovudine glucuronide formation in healthy subjects.
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Introduction
Rifampicin (RIM) and rifabutin (RIB),
whose chemical structures are given in
Figure 1, are two rifamycin derivatives used
for the treatment of pulmonary tuberculo-
sis. In addition to being more potent than
RIM against M. tuberculosis, RIB proved to
be beneficial to patients with chronic drug-
resistant pulmonary tuberculosis unrespon-
sive to previous treatments, including those
containing RIM.
This review deals mainly with the
induction and autoinduction properties
of RIM and RIB in humans. However,
data obtained in laboratory animals will
also be discussed, as it appears that
important species differences have been
observed concerning the induction prop-
erties ofRIM.
Inducton Properties ofRifampicin
andRifabutin inAnimals
Pessayre and Mazel (1) found that repeated
administration of RIM to male ICR-Swiss
mice (50 mg/kg, ip, daily for 6 days)
affected the components of the hepatic
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mixed-function oxidase system as well as
enzymatic activity. Liver weight,
cytochrome P450, total heme, and
NADPH-cytochrome c reductase were all
significantly increased, as was the metabo-
lism ofethylmorphine, zoxazolamine, ben-
zpyrene, and 17,B-estradiol. In contrast to
the above substrates, aniline hydroxylation
and the glucuronylconjugation ofp-nitro-
phenol were essentially unaffected. In male
Sprague-Dawley rats given RIM at the dose
of 50 mg/kg, ip, twice daily for 6 days, no
significant effects were observed on liver
microsomal activity against five different
substrates. Hexobarbital sleeping time,
hepatic microsomal protein, cytochrome
P450, and liver weight were also unaf-
fected. Thus, there is a sharp species differ-
ence with respect to induction of hepatic
microsomal mixed-function oxidase activ-
ity by RIM. The absence ofRIM induction
of drug-metabolizing enzymes in rats had
been previously reported (2).
Species differences in RIM induction
have been seen by multiple investigators.
Barone et al. (3) found that pentobarbital
and hexobarbital metabolism and hepatic
cytochrome P450 levels were increased in
mice treated with RIM, whereas no
changes were observed in rats and guinea
pigs. However, an RIM-induced rise in
hepatic smooth endoplasmic reticulum was
reported in guinea pigs (4). The inductive
properties of RIM in mice were further
characterized in comparison with known
inducers by Heubel and Netter (5) and
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Figure 1. Chemical structures of rifampicin and
rifabutin.
Tredger et al. (6), using male NMRI and
C57Bl6 mice, respectively. The latter strain
was also responsive to polycyclic hydrocar-
bon induction (7). Although some appar-
ent contradictions were observed among
the different studies, RIM behaved as an
atypical inducer in mice, and may prefer-
entially induce the hepatic mixed-function
oxidation of large polycyclic cytochrome
P450 substrates.
In contrast to mouse, rat is far less
sensitive to RIM induction. In a recent
work (8) where Wistar rats were treated
orally with a 200 mg/kg dose ofRIM for
7 days, no induction of the hepatic
cytochrome P450 system could be
Environmental Health Perspectives 101STROLIN BENEDETTIETAL.
demonstrated. In the New Zealand rab-
bit, Daujat et al. (9) reported a strong
induction of hepatic cytochrome
P4503A subfamily after ip administra-
tion of50 mg/kg/day RIM for 4 days. In
the same study, induction of hepatic
cytochrome P4503A was also found in
Wistar rats given the much higher dose
of 300 to 600 mg/kg/day RIM, mixed
into the ground chow, for 3 weeks.
Specifically the average erythromycin-
demethylase activities in liver micro-
somes of these rats were 0.92, 3.83,
2.11, and 4.02 nmol/mg/min in un-
treated and RIM-treated female and
male rats, respectively.
Concerning the inductive properties
of RIB, no changes in cytochrome P450
concentrations or NADPH-cytochrome
c reductase, aminopyrine demethylase
and aniline hydroxylase activities in liver
microsomes were found in a limited
study (10), in which RIB was given
orally to female and male mice at doses
up to 64 mg/kg/day for 5 to 10 days. In
the same study when RIM was adminis-
tered to mice according to the same
schedule, the inducing properties of
RIM were confirmed.
Induction Properties ofRifampicin
andRifibutin in Humans
Perucca et al. (11) compared the inductive
properties ofRIM and RIB in eight normal
subjects according to a randomized cross-
over design. Each subject received two sep-
arate 7-day oral treatments with either
RIM or RIB at the effective dosage used in
clinical trials for the treatment oftubercu-
losis, 600 mg and 300 mg, respectively.
There was a wash-out interval ofat least 8
weeks between treatments. Antipyrine was
administered iv 2 days before each treat-
ment and blood samples were collected for
the determination of plasma antipyrine
pharmacokinetics. Blood was also collected
for the measurement ofplasma y-glutamyl-
transpeptidase (GGT) activity. Urine was
collected for the measurement of antipy-
rine metabolites, 6-p-hydroxycortisol (6-n-
OHC) and 17-hydroxycorticosteroids
(17-OHCS). The same blood and urine
sampling schedule was repeated on day 7
of each treatment period, when a second
antipyrine injection was given.
Antipyrine is oxidized to three main
metabolites in humans: norantipyrine
(NORA), 4-hydroxyantipyrine (OHA),
and 3-hydroxymethylantipyrine (HMA)
(12). There is evidence that the different
metabolites are products ofdifferent forms
of cytochrome P450. While cytochrome
P4502D6, the isozyme of cytochrome
P450 responsible for the debrisoquine/
sparteine polymorphism, does not appear
to be involved (13,14), controversial opin-
ions have been expressed as to the partici-
pation of the cytochrome P4503A
subfamily in the metabolism ofantipyrine
(15,16).
Administration of RIM was associated
with a 40% shortening of the antipyrine
half-life and a marked increase in antipy-
rine clearance. RIB caused a 25% decrease
in antipyrine half-life and a moderate
increase in antipyrine clearance,-and these
changes were significantly lower than those
caused by RIM. After RIM the rate offor-
mation, expressed as clearance for produc-
tion (17), of NORA, OHA and HMA
increased by 177, 91, and 70%, respec-
tively, whereas only the clearance for pro-
duction of NORA was significantly
increased by 53% after RIB. These results
are in reasonable agreement with those
reported in previous studies (17,18), in
which RIM was shown to preferentially
stimulate the formation of NORA in
humans. This is in contrast to phenytoin
and carbamazepine which mostly enhance
the formation of OHA, to a lesser degree
that of HMA, and have no effect on the
NORA pathway (19). Plasma GGT activ-
ity showed a slight but statistically signifi-
cant increase after RIM and remained
unchanged after RIB, thereby confirming
the poor value ofthis enzyme as an index
of the mixed-function oxidase activity
(20-22). Urinary 6-,-OHC increased after
both drugs, but the changes were signifi-
cantly more marked after RIM. On aver-
age, the rise in 6-P-OHC/17-OHCS ratio
over baseline (23) was 320% after RIM as
compared to 64% after RIB.
6-J-OHC is a minor metabolite ofcor-
tisol formed primarily in the endoplasmic
reticulum of hepatocytes by the mixed
function oxidases and excreted unconju-
gated in urine. Ged et al. (24) have
recently shown that the daily administra-
tion ofa 600 mg dose ofRIM for 4 days to
patients results in the increase in urinary 6-
P-OHC with a parallel increase in activity
ofliver microsomal cortisol 6,-hydroxylase
and erythromycin N-demethylase, a
marker of the cytochrome P4503A sub-
family, whereas no concomitant increase is
observed for the microsomal ethoxyre-
sorufin O-deethylase, a marker of the
cytochrome P4501A subfamily. These
results indicate that the cytochrome
P4503A subfamily is predominantly
involved in cortisol 60-hydroxylation, so
that the increase in urinary excretion of6-
f-OHC can be considered as a marker of
human hepatic cytochrome P4503A induc-
tion. In humans, cytochrome P4503A is
involved in the metabolism ofa large num-
ber ofdrugs, among which is ethynylestra-
diol, a constituent of oral contraceptives
(25). Thus, the older works of Bolt et al.
(26) and Back et al. (27) showing a rise in
estradiol and ethynylestradiol hydroxylation
in hepatic microsomal preparations from
RIM-treated patients and a significant alter-
ation of the plasma pharmacokinetics of
ethynylestradiol in women treated with
RIM, should be considered as a further evi-
dence that RIM substantially induces the
cytochrome P4503Asubfamily.
RIB has been found to be effective for
the treatment of mycobacterium avium
complex (MAC) infection in patients with
AIDS (28,29), and zidovudine (AZT) is
currently used to treat these patients.
Metabolism ofAZT is species-dependent.
In man, AZT is mainly excreted in urine as
5'--glucuronide (GAZT). Following oral
administration, the mean urinary recovery
ofAZT and GAZT was 14 and 75% ofthe
dose, respectively (30). In contrast, rats
orally dosed with AZT excreted 78% of
the dose as unchanged drug and less than
2% as GAZT in urine, while 20% of the
dose was recovered as 3-aminoderivative in
feces (31,32). Since AZT is mainly inacti-
vated by glucuronyl conjugation in
humans, a study was carried out in healthy
volunteers to examine whether, and even-
tually to what extent, RIB and RIM might
influence the glucuronyl conjugation of
AZT. The inductive effect of RIM on glu-
curonidation ofdrugs and endobiotics in
humans remains a controversial question.
Thus, although RIM has been shown to
induce the formation ofparacetamol glu-
curonide in humans (33,34), as isoniazid
was given concomitantly and isoniazid was
found to induce uridine diphosphate glu-
curonyltransferase (UDP-GT) activity in
hamsters (35), this effect might be, at least
partly, due to isoniazid. Bilirubin under-
goes glucuronidation prior to excretion in
the bile. There are data suggesting that
RIM might enhance the hepatic clearance
ofbilirubin (36-38). However, in a study
conducted in subjects given RIM for 30
days, bilirubin GT activity was reported to
be insensitive to the treatment (39). In
contrast, the paranitrophenol GT activity
was significantly increased in these sub-
jects. In humans, compound glucuronida-
tion involves a number ofisozymes, which
probably differ in terms ofsubstrate speci-
ficity and regulation (40). This is why it
was important to examine whether the
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activity ofthe GTs involved in the metabo-
lism ofAZT is modified by the administra-
tion ofrifamycin derivatives.
Two groups of ten healthy volunteers
were treated with AZT (200 mg, po) on
day 1, then with RIB (300 mg/day, po) or
with RIM (600 mg/day) from day 2 to day
11. On day 12 they received a further dose
of200 mg AZT. Plasma levels ofAZT and
of GAZT were assayed by HPLC. Urinary
excretion could be studied only for AZT
(41). Cma and AUCO_o ofAZT were sig-
nificantly decreased by either treatment,
whereas no changes were observed in half-
life. Eleven percent ofthe dose was recov-
ered in urine as AZT and this value was
not modified by RIB, but was significantly
decreased by RIM. No significant differ-
ence was observed for the plasma Cmax,
AUCO0o. and half-life values of GAZT
between pre- and postdosing with RIB or
RIM. Thus, RIB and RIM have been
found to influence the metabolism ofAZT
in healthy subjects; this effect appears to be
more marked for RIM than for RIB, at
least under the experimental conditions of
this study. The changes in the metabolism
ofAZT caused by the two rifamycin deriv-
atives remain to be determined. It does not
seem, however, that the phenobarbital-
induced UDP-GT form (42) responsible
for the formation of GAZT is involved.
Although the recovery ofAZT and GAZT
in human urine accounts for about 90% of
the dose, it may be that a minor oxidative
pathway is induced by the antibiotics, or
that the two rifamycin derivatives induce
intracellular kinases converting AZT to
nucleotide forms (43).
Autoinduction Properties ofRifibutin
andRifampicin in Humans
RIB is metabolized in humans to more
than 20 compounds (44). Besides the
unchanged drug, 25-O-deacetyl RIB has
been identified in human urine together
with four metabolites produced by oxida-
tive pathways: 31-OH-RIB, 32-OH-RIB,
32-OH-25-O-deacetyl-RIB and 25-0-
deacetyl-RIB-piperidine-N-oxide.
Preliminary data on 3-glucuronidase
hydrolysis of human urine after RIB
administration showed the presence of
small amounts of conjugated RIB (P
Duchene, unpublished observation).
Autoinduction ofRIB metabolism was
studied in seven healthy male volunteers
who received 450 mg RIB orally on day 1.
Then, from day 6 onwards, the same daily
dose was given for 10 days (45). Plasma
kinetics of RIB, 25-O-deacetyl-RIB and
31-OH-RIB were measured after the single
and the last dose using HPLC with UV
detection. Monitoring ofplasma levels dur-
ing the repeated treatment was also carried
out 24 hr after the third, fifth, seventh
and ninth dose. Urinary excretion of
unchanged RIB, 25-0-deacetyl-RIB and
31-OH-RIB was also determined after the
single and the last dose of the repeated
treatment. The plasma pharmacokinetic
parameters of RIB after the single and the
tenth dose of the repeated treatment were
calculated by model independent analysis.
The experimental AUCO-24hr after
the tenth dose, i.e., at steady state, was
significantly lower than the experimental
AUCo,0 after the single dose. In contrast,
the difference in the half-life ofelimination
did not attain significance. The experimen-
tal and theoretical plasma levels of
unchanged RIB 24 hr after the single dose,
and 24 hr after the third, fifth, seventh,
ninth and tenth dose ofthe repeated treat-
ment were compared and, from the fifth
dose on, the experimental values were sig-
nificantly lower than the theoretical ones.
These results clearly demonstrate that RIB
induces its own metabolism. The plasma
levels of the 25-O-deacetyl-RIB decreased,
whereas those of 31-OH-RIB after re-
peated administration increased. The
absence of a decrease in the half-life of
elimination after RIB autoinduction could
be expected for a drug with a high hepatic
extraction ratio, as already suggested for
metoprolol and propranolol, whose elimi-
nation half-lives were unchanged after
repeated administration of RIM (46,47).
It may also be that the metabolism of RIB
is not only hepatic but also extrahepatic,
with the gut participating extensively in its
metabolism. Induction ofgut enzymes by
RIB may occur, as suggested for RIM; this
might explain why the AUC was signifi-
cantly reduced after repeated administra-
tion of RIB without a significant decrease
in half-life ofelimination.
Autoinduction of RIM metabolism in
humans was studied by Acocella et al. (48)
and more recently by Loos et al. (49). In
the study by Acocella et al., three dose lev-
els, each in six healthy subjects, were inves-
tigated: 900 mg and 600 mg once daily
and 300 mg administered at 12-hr inter-
vals. On days 1, 4, 6, and 14 oftreatment,
serum kinetics of RIM were carried out
using a microbiological, nonspecific
method. The pharmacokinetic parameters
after the single and the repeated doses were
calculated by model independent analysis.
The half-life value of RIM was much
shorter than that ofRIB-between 2.6 and
5.1 hr following single doses. As observed
for RIB, the AUC and Cmin values ofRIM
decreased after repeated administration,
whereas, in contrast to RIB, the half-life of
elimination also decreased. The authors
suggested that these changes occur mainly
during the first 6 days of treatment.
Deacetylation to form deacetyl-RIM and
hydrolysis to afford formyl-RIM occur dur-
ing RIM metabolism (50), and urine
deacetyl-RIM decreased after repeated
administration of RIM (49). The possible
occurrence ofvery small amounts ofthe N-
demethylderivative (51) and of RIM-
quinone (26,52) in human urine clearly
needs further supportive evidence, as also
the possible induction (50) of RIM-glu-
curonidation (53).
Conclusions
The two rifamycin derivatives, RIM and
RIB, induce several cytochrome P450
enzymes in humans, including those belong-
ing to the cytochrome P4503A subfamily.
The lack ofinduction ofthe cytochrome
P4501A subfamily and of cytochrome
P4502D6 (14) observed with RIM has still
to be demonstrated for RIB. Both RIM and
RIB induce their own metabolism. In the
case ofRIB, there is evidence that hydroxyla-
tion ofthe ansa chain is among the meta-
bolic pathways induced, whereas in the case
ofRIM the induced pathways have not been
identified. Following RIM autoinduction,
both the area under the plasma concentra-
tion-time curve and the half-life ofelimina-
tion are reduced, whereas in the case ofRIB
autoinduction, the half-life ofelimination is
not altered significantly. Although RIM may
induce the glucuronidation ofsome xenobi-
otics in humans, neither RIM nor RIB
appear to induce the glucuronyltransferase(s)
responsible for the metabolism ofAZT.
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